[1]陈鹄,范丽,包蒙,等.余甘子提取物通过蛋白激酶B/哺乳动物雷帕霉素靶蛋白通路对肺癌细胞A549恶性生物学行为的影响[J].陕西医学杂志,2026,(1):17-21,28.[doi:DOI:10.3969/j.issn.1000-7377.2026.01.003]
　CHEN Hu,FAN Li,BAO Meng,et al.Effect of phyllanthus emblica extract on malignant biological behavior of lung cancer cell A549 through Akt/mTOR pathway[J].,2026,(1):17-21,28.[doi:DOI:10.3969/j.issn.1000-7377.2026.01.003]
点击复制

余甘子提取物通过蛋白激酶B/哺乳动物雷帕霉素靶蛋白通路对肺癌细胞A549恶性生物学行为的影响

《陕西医学杂志》[ISSN:1000-7377/CN:61-1281/TN]

卷:
期数:
2026年1期
页码:
17-21,28
栏目:
基础研究
出版日期:
2026-01-05

文章信息/Info

Title:
Effect of phyllanthus emblica extract on malignant biological behavior of lung cancer cell A549 through Akt/mTOR pathway
作者:
陈鹄; 范丽; 包蒙; 田世奎
（苏州大学苏州永鼎医院临床研究院肿瘤科，江苏 苏州 215000）
Author(s):
CHEN Hu; FAN Li; BAO Meng; TIAN Shikui
(Department of Oncology,Clinical Research Institute,Suzhou Yongding Hospital,Soochow University,Suzhou 215000,China)
关键词:
余甘子提取物; 蛋白激酶B/哺乳动物雷帕霉素靶蛋白通路; 肺癌; 侵袭; 迁移; 凋亡
Keywords:
Phyllanthus emblica extract; Akt/mTOR pathway; Lung cancer; Invasion; Migration; Apoptosis
分类号:
R 734.2
DOI:
DOI:10.3969/j.issn.1000-7377.2026.01.003
文献标志码:
A
摘要:
目的：探讨余甘子提取物通过蛋白激酶B/哺乳动物雷帕霉素靶蛋白（Akt/mTOR）通路对肺癌细胞A549恶性生物学行为的影响。方法：选取人非小细胞肺癌A549细胞，分为对照组（空白未处理）、余甘子提取物低剂量组（加入50 μg/ml）、中剂量组（加入100 μg/ml）、高剂量组（加入200 μg/ml）、阳性药组（加入100 nmol/L雷帕霉素），采用CCK8法、流式细胞术检测各组A549细胞存活和凋亡率，Transwell小室实验、细胞划痕试验测各组细胞侵袭和迁移能力，Western blot法测各组细胞中Akt、p-Akt、mTOR、p-mTOR蛋白表达。取各组肺癌A549细胞，建立小鼠移植瘤模型，记录各组小鼠移植瘤生长和小鼠存活变化。结果：与对照组比较，低、中、高剂量余甘子提取物组、阳性药组小鼠肿瘤体积、肿瘤质量降低，且呈剂量依赖性（均P＜0.05）。低、中、高剂量余甘子提取物组、阳性药组的A549细胞活力、侵袭、迁移能力及p-Akt、p-mTOR蛋白表达均低于对照组（均P＜0.05），且阳性药组、高剂量组低于中剂量组，中剂量组低于低剂量组（均P＜0.05）。低、中、高剂量余甘子提取物组的A549细胞凋亡率高于对照组，且呈剂量依赖性（均P＜0.05）。结论：余甘子提取物可抑制Akt/mTOR通路活性，使肺癌A549细胞侵袭、迁移受到干扰，抑制裸鼠皮下成瘤速度，并诱导细胞凋亡。
Abstract:
Objective:To investigate the effect of Phyllanthus emblica extract on the malignant biological behavior of lung cancer cell A549 through protein kinase B/mammalian target of rapamycin (Akt/mTOR) pathway.Methods：Human non-small cell lung cancer A549 cells were selected and divided into control group (blank untreated),low dose group (50 μg/ml),medium dose group (100 μg/ml) and high dose group (200 μg/ml).CCK8 method and flow cytometry were used to detect the survival and apoptosis rate of A549 cells in each group.Transwell chamber assay and cell scratch test were used to detect the invasion and migration ability of each group.Western blot was used to detect the protein expression of Akt,p-Akt,mTOR and p-mTOR in each group.Lung cancer A549 cells were collected from each group to establish a mouse model of transplanted tumor.The growth of transplanted tumor and survival of mice in each group were recorded.Results:Compared with the control group,the tumor volume and weight of the mice in the low-,medium-,and high-dose Phyllanthus emblica extract groups were decreased in a dose-dependent manner (all P<0.05).The cell viability,invasion and migration abilities and the expressions of p-Akt and p-mtor proteins in A549 cells were significantly lower in the low-,medium- and high-dose EMB groups than in the control group (all P<0.05),and the high dose group was lower than the middle dose group,and the middle dose group was lower than the low dose group (all P<0.05).The apoptosis rate of A549 cells in the low-,medium- and high-dose EmB groups was higher than that in the control group,and showed a dose-dependent manner (all P<0.05).Conclusion:Phyllanthus emblica extract can inhibit the activity of Akt/mTOR pathway,interfere with the invasion and migration of lung cancer A549 cells,inhibit the rate of subcutaneous tumor formation in nude mice,and induce cell apoptosis.

参考文献/References:

[1]王海志,张红,郭晓蘅,等.血清免疫球蛋白、Foxp3水平与晚期非小细胞肺癌患者纳武单抗治疗效果的关系[J].中国免疫学杂志,2025,41(2)：413-417.
[2]OUDKERK M,LIU S,HEUVELMANS M A,et al.Lung cancer LDCT screening and mortality reduction-evidence,pitfalls and future perspectives[J].Nat Rev Clin Oncol,2021,18(3)：135-151.
[3]李欢,邱紫欣,徐文洁,等.木犀草素通过增加ROS的产生和下调AKT/mTOR通路及HO-1蛋白表达抑制肺癌A549细胞增殖[J].南方医科大学学报,2024,44(12)：2367-2374.
[4]崔启迪,吕光耀,张金杰,等.葫芦素B通过AKT/mTOR和MAPK信号通路诱导非小细胞肺癌细胞自噬[J].现代肿瘤医学,2024,32(16)：2929-2936.
[5]INNETS B,THONGSOM S,PETSRI K,et al.Akt/mTOR targeting activity of resveratrol derivatives in non-small lung cancer[J].Molecules,2022,27(23)：8268.
[6]杨匹容,蒋兰,刘宇凤,等.非小细胞肺癌小细胞转化的分子特征及治疗进展[J].肿瘤预防与治疗,2025,38(1)：75-81.
[7]陈晓敏,杨柳,陈秀梅,等.余甘子溶液口腔喷雾对鼻咽癌放射性口干症患者的干预效果[J].护理学杂志,2024,39(18)：53-56.
[8]朱英环,孟宪生,包永睿,等.余甘子总酚酸和总黄酮配伍抑制肝癌细胞增殖及对免疫功能的调节作用[J].中国实验方剂学杂志,2012,18(3)：132-135.
[9]关陟昊,单治易,王雪,等.基于“成分-靶点-通路”的余甘子网络药理学研究[J].中华医学图书情报杂志,2021,30(9)：13-23.
[10]DETTERBECK F C,WOODARD G A,BADER A S,et al.The proposed ninth edition TNM classification of lung cancer[J].Chest,2024,166(4)：882-895.
[11]刘晓菊,姚芮,杨学知,等.早期非小细胞肺癌胸腔镜下肺亚段切除术与肺段切除术治疗效果比较[J].陕西医学杂志,2024,53(8)：1069-1072.
[12]夏延贞,霍寅萍,王龙珍,等.余甘子提取物通过miR-34a对高糖诱导的PC12细胞损伤的保护作用[J].毒理学杂志,2024,38(1)：43-50.
[13]刘晓晖,吕乔,吉雄,等.余甘子化学成分研究[J].中成药,2023,45(2)：458-462.
[14]尹可欢,罗晓敏,丁翼,等.余甘子及其活性成分肝保护作用及机制的研究进展[J].中草药,2022,53(1)：295-307.
[15]张洪岩,刘欢,朱宝杰,等.余甘子提取物调控LINC01772/miR-153对肺癌细胞A549生物学行为的影响[J].现代生物医学进展,2024,24(5)：841-848.
[16]李清,李江,黄诗娅,等.吉祥草配伍余甘子不同提取物及其有效部位组合对Lewis肺癌小鼠模型的药效学比较[J].亚太传统医药,2018,14(10)：18-21.
[17]黄兴文,刘炜.苗药吉祥草配伍余甘子抗Lewis肺癌细胞增殖组分的筛选[J].中医药导报,2023,29(11)：6-10.
[18]IKSENPOTHONGSRISIT S,PONGRAKHANANON V.Targeting the PI3K/AKT/mTOR signaling pathway in lung cancer：An update regarding potential drugs and natural products[J].Molecules,2021,26(13)：4100.
[19]LIU H,GUO W,WANG T,et al.CD36 inhibition reduces non-small-cell lung cancer development through AKT-mTOR pathway[J].Cell Biol Toxicol,2024,40(1)：10.
[20]项莹,韩军,武前枝.白杨素通过促进氧化应激介导的AKT/mTOR通路失活诱导肺癌细胞发生自噬[J].临床肺科杂志,2024,29(7)：1055-1065.
[21]霍怡杉,徐晓慧,马秀敏,等.GINS1通过激活Notch/PI3K/AKT/mTORC1信号通路增强肺腺癌细胞糖酵解、增殖和转移[J].中国肺癌杂志,2024,27(10)：735-744.
[22]杨朋,钱军,陈文飞,等.木犀草素对人非小细胞肺癌A549细胞凋亡及自噬的影响[J].中成药,2022,44(8)：2667-2671.
[23]林增海,陆军,王凯松.槲皮素对5-FU诱导的结直肠癌SW480细胞耐药及自噬调控机制研究[J].陕西中医,2021,42(10)：1338-1343.
[24]王新茹,李丽玲,姜婷婷,等.基于网络药理学和分子对接探究余甘子治疗肝细胞癌的分子机制[J].中西医结合肝病杂志,2022,32(2)：154-160.
[25]曹雪婷,吴博雅,陈静.刺五加苷B介导PI3K/Akt/mTOR通路诱导肺癌细胞凋亡和自噬[J].中国中药杂志,2023,48(24)：6693-6701.

备注/Memo

备注/Memo:
国家自然科学基金资助项目（81972174）；江苏省卫生健康委员会科研项目（2024WZRD11062）
更新日期/Last Update: 2026-01-05